A Multi-centre, Prospective, Open-label, Single-arm, Non-interventional, Post Marketing Surveillance (PMS) Study of Tresiba (Insulin Degludec) to Evaluate Long Term Safety and Efficacy in Patients With Diabetes Mellitus in Routine Clinical Practice in India
Phase of Trial: Phase IV
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Insulin degludec (Primary)
- Indications Diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 28 Jul 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 20 Feb 2017 Planned End Date changed from 1 Aug 2017 to 1 Apr 2017.